IGF-1 LR3: Mechanism, Pharmacology and Laboratory Use
By Peptura Research Team/22 May 2026/7 min read
What IGF-1 LR3 Is
IGF-1 LR3, or Long R3 Insulin-like Growth Factor 1, is a synthetic analogue of human insulin-like growth factor 1 carrying two structural changes: arginine substituted for glutamic acid at position 3 of the mature IGF-1 sequence, and a 13-amino-acid extension on the N-terminus. Together these transform the peptide's pharmacokinetics relative to native IGF-1, producing a research tool used across in-vitro and in-vivo studies of growth factor signalling, cell proliferation, and myogenesis.
Peptura supplies IGF-1 LR3 as research-grade lyophilised powder for in-vitro laboratory research use only.
The Problem With Native IGF-1
Native IGF-1 has a very short serum half-life, roughly 10 to 12 minutes in unbound form. The reason is that IGF-1 binds a family of six insulin-like growth factor binding proteins (IGFBPs), IGFBP-3 in particular, which lock it away in a high-molecular-weight ternary complex, after which the free fraction is cleared quickly. For any application needing sustained receptor activation, that brevity is a real constraint, and the binding-protein sequestration muddies dose-response analysis on top of it.
What the Modifications Do
Both changes in IGF-1 LR3 are aimed at cutting IGFBP binding and lengthening circulating half-life. The arginine substitution at position 3 lowers affinity for the IGFBPs without disturbing binding to the IGF-1 receptor. The 13-amino-acid N-terminal extension reduces IGFBP binding further while shielding the peptide from amino-peptidase degradation. The net effect is a peptide with a circulating half-life reported in the region of 20 to 30 hours in some preclinical models, far beyond native IGF-1, with less binding-protein sequestration and so a larger receptor-available fraction.
Dunaiski and colleagues reported in the Journal of Endocrinology in 1997 that Long-R3-IGF-1 given to pigs altered growth hormone, IGFBP-3, and endogenous IGF-1 concentrations, showing that the modified peptide produced measurable systemic effects distinct from native IGF-1.
Mechanism of Action
IGF-1 LR3 acts as an agonist at the type 1 insulin-like growth factor receptor (IGF-1R), a tyrosine kinase receptor found widely across mammalian tissues. Binding triggers autophosphorylation and recruitment of insulin receptor substrate proteins (IRS-1, IRS-2), launching two main downstream cascades.
The PI3K/Akt pathway carries the anabolic effects: protein synthesis through mTOR activation, suppression of apoptosis through Bad phosphorylation, and modulation of glucose metabolism. The Ras/MAPK pathway carries proliferative and differentiation signalling. How strongly each is engaged depends on cell type and downstream context, which is part of what makes IGF-1 LR3 so versatile across tissue models.
Research Applications
IGF-1 LR3 turns up wherever sustained IGF-1 receptor activation is needed. In skeletal muscle research it is used to study myoblast proliferation, myotube fusion, and satellite cell activation in cell-culture models of myogenesis. In biotechnology, cell-culture protocols use it as a serum-free growth supplement to support proliferation of mammalian cell lines, including stem cell and induced pluripotent stem cell work. Regeneration models examine it in muscle, nerve, and connective-tissue repair.
Hammon and Blum reported in the American Journal of Physiology in 1997 that Long-R3-IGF-1 administration modulated the somatotropic axis in neonatal calves, including endogenous IGF-1 levels and IGFBP-2 expression, an illustration of its value in research on growth factor regulation of the GH/IGF axis.
Native IGF-1 or the Analogue?
Which to choose comes down to the question. Studies needing acute, short-duration IGF-1 receptor activation in tightly controlled in-vitro settings often reach for native IGF-1 to reproduce physiological pulsatile signalling. Studies needing sustained activation, or cell-culture systems where binding-protein sequestration confounds dose-response, generally use IGF-1 LR3 for a steadier, longer-acting stimulus. The two are not interchangeable in experimental design.
Laboratory Handling
IGF-1 LR3 comes as lyophilised powder. Store at -20°C before reconstitution. Reconstitute with bacteriostatic water by running it slowly down the inner wall of the vial and swirling gently. Some protocols use a slightly acidic reconstitution buffer for IGF analogues, so check protocol-specific documentation where relevant. Keep the reconstituted solution at 2-8°C and use within four weeks. The peptide reconstitution guide covers the method in detail.
Sourcing in the UK
Peptura supplies research-grade IGF-1 LR3 as lyophilised powder with full third-party HPLC documentation published on the product page. Same-day UK dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. For in-vitro laboratory research use only, not for human consumption.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.